Found: 19
Select item for more details and to access through your institution.
IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model.
- Published in:
- Frontiers in Neurology, 2024, p. 1, doi. 10.3389/fneur.2024.1356300
- By:
- Publication type:
- Article
Methods for preparing tissue microarray slides using xenografts with different levels of HER2 expression to standardize HER2 detection.
- Published in:
- Pathology International, 2023, v. 73, n. 1, p. 39, doi. 10.1111/pin.13288
- By:
- Publication type:
- Article
Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 860, doi. 10.1007/s12185-022-03320-0
- By:
- Publication type:
- Article
PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8<sup>+</sup> T cells in hematogenous metastasis model with lymphocyte infusion.
- Published in:
- Clinical & Experimental Metastasis, 2022, v. 39, n. 2, p. 335, doi. 10.1007/s10585-021-10135-6
- By:
- Publication type:
- Article
Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1<sup>low</sup> and immune desert-like mouse tumors.
- Published in:
- Oncology Reports, 2022, v. 47, n. 2, p. N.PAG
- By:
- Publication type:
- Article
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-93113-y
- By:
- Publication type:
- Article
Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model.
- Published in:
- Clinical & Experimental Metastasis, 2020, v. 37, n. 1, p. 199, doi. 10.1007/s10585-019-10008-z
- By:
- Publication type:
- Article
T2∗ Relaxation Time Obtained from Magnetic Resonance Imaging of the Liver Is a Useful Parameter for Use in the Construction of a Murine Model of Iron Overload.
- Published in:
- Contrast Media & Molecular Imaging, 2019, p. 1, doi. 10.1155/2019/7463047
- By:
- Publication type:
- Article
Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model.
- Published in:
- Oncology Reports, 2019, v. 42, n. 3, p. 1057, doi. 10.3892/or.2019.7211
- By:
- Publication type:
- Article
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.
- Published in:
- International Journal of Oncology, 2017, v. 51, n. 2, p. 425, doi. 10.3892/ijo.2017.4036
- By:
- Publication type:
- Article
The effect of frequency of C.E.R.A. administration on the contribution of dietary iron for erythropoiesis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
- Published in:
- Oncology Reports, 2016, v. 36, n. 2, p. 626, doi. 10.3892/or.2016.4902
- By:
- Publication type:
- Article
Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
- Published in:
- International Journal of Cancer, 2016, v. 138, n. 4, p. 1024, doi. 10.1002/ijc.29848
- By:
- Publication type:
- Article
Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.
- Published in:
- International Journal of Hematology, 2014, v. 99, n. 5, p. 561, doi. 10.1007/s12185-014-1554-6
- By:
- Publication type:
- Article
Serotonergic mechanisms involved in the attentional and vigilance task performance of rats and the palliative action of aniracetam.
- Published in:
- Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, v. 361, n. 5, p. 521, doi. 10.1007/s002100000222
- By:
- Publication type:
- Article
Aniracetam attenuates the 5-HT<sub>2</sub> receptor-mediated head-twitch response in rodents as a hallucination model.
- Published in:
- Drug Development Research, 1998, v. 44, n. 4, p. 131, doi. 10.1002/(SICI)1098-2299(199808)44:4<131::AID-DDR1>3.0.CO;2-S
- By:
- Publication type:
- Article
Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam.
- Published in:
- Drug Development Research, 1998, v. 43, n. 2, p. 85, doi. 10.1002/(SICI)1098-2299(199802)43:2<85::AID-DDR1>3.0.CO;2-L
- By:
- Publication type:
- Article